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Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n= 400)
could be optimized by doubling the dose (n= 420), adding interferon (IFN) (n= 430) or cytarabine (n= 158) or using IM after IFN-
failure (n= 128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm
study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year
overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between
IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations,
comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment
optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For
responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival
is more determined by patients’ and disease factors than by initial treatment selection. Although improvements are also needed for
refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.
Leukemia (2017) 31, 2398–2406; doi:10.1038/leu.2017.253
INTRODUCTION
Chronic myeloid leukemia (CML)-study IV was designed to explore
whether treatment with imatinib (IM) at a dose of 400 mg/day as
used in the International Randomized Study on Interferon (IFN)
and STI571 (IRIS)1,2 could be improved by doubling the dose or by
combining IM with IFN or cytarabine. Primary goals were the
comparative response and long-term survival analyses of the
experimental arms vs IM400 mg. Molecular monitoring of all
patients was an integral part of the study from the beginning. The
study has generated new insights in the relevance of molecular
monitoring,3,4 of comorbidities,5 additional chromosomal
aberrations6,7 and deep molecular response.8 CML-study IV has
also shown that IM at 800 mg results in significantly earlier
cytogenetic and molecular responses than IM400 mg.3,8 Various
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observational and randomized studies have tried to improve IM-
treatment by combination with IFN, cytarabine or a dose increase
to 600 or 800 mg9–16 and have achieved earlier and deeper
responses. In no instance a better survival was reported after
median observation periods up to 3.5 years. Two studies have
compared survival with IM400 mg and 2nd generation tyrosine
kinase inhibitors (2G-TKI). After 5 years, 2G-TKI showed earlier and
deeper responses than IM400 mg, but no survival advantage.17,18
CML-study IV was powered to detect a 5% survival difference after
5 years. We here report survival outcome after a median
observation time of close to 10 years.
PATIENTS AND METHODS
Study design and treatment strategy have been published previously.3,8
In brief, newly diagnosed CML patients in chronic phase (CP)
were randomized into a 5-arm study comparing IM400 mg/day vs
IM400 mg/day in combination with IFN vs IM400 mg/day in
combination with low-dose cytarabine vs IM400 mg/day after IFN-failure
vs IM800 mg/day. Recruitment was from July 2002 through March 2012.
There was no upper age limit. Exclusion criteria were pretreatment except
with hydroxyurea or anagrelide, no consent, pregnancy, participation in
another study, second neoplasia and serious illness that made per protocol
participation a priori unlikely. Only low- and intermediate-risk patients
were randomized to primary IFN and, during a pilot-phase of 3 years, only
high-risk patients to IM800 mg/day. After 3 years, recruitment to IM plus
cytarabine and IM after IFN-failure was terminated, and the IM800 mg/day
arm started to include non-high-risk patients, too. Data lock was on 19
September 2016.
Initial treatment in all study arms except IM-after-IFN-failure was
IM400 mg once daily. If no complete hematologic remission was reached
after 2 months or no partial cytogenetic remission (PCyR) after 6 months, a
dose increase was permitted. If IM-treatment failed, stem-cell transplanta-
tion or risk-adapted drug treatment (hydroxyurea, cytarabine,
intensive chemotherapy) was recommended - depending on type of
mutation and degree of proliferation or progression. After availability,
either dasatinib or nilotinib was recommended. Participation of
IM-resistant or intolerant patients in the dasatinib and nilotinib phase II
studies was permitted. The first patient was switched to 2G-TKI (dasatinib)
on 30 March, 2005.
IFN, subcutaneous cytarabine and the full 800 mg/day dose were
administered after a 6-week run-in period with IM 400 mg/day to avoid
cytopenias.8 The IM-dose could be reduced according to tolerability.
Initial primary goal of CML-study IV were comparative response
probabilities. Long-term primary goal was comparative survival (study
protocol in the Supplementary Appendix). The strategy was to give more
intensive treatment early since this has improved outcome.19
Definitions and end points
Definitions followed the ELN (European LeukemiaNet) recommendations.20,21
Risk assignment was made according to Euro-score.22 IFN-failure was defined
as no complete hematologic remission after 6 months or not at least PCyR
after 21 months, loss of complete hematologic remission or complete
cytogenetic remission, or higher-grade AE. Overall survival (OS) was defined as
the time between diagnosis and death resulting from any cause. Progression-
free survival (PFS) considered the additional events accelerated phase and
blast crisis (BC). Death unrelated to CML was defined as death without prior
progression and unrelated to CML-therapy. Death due to CML was stratified
according to the European treatment and outcome study (EUTOS)-long-term-
survival (ELTS) score.23 All living patients were censored at the time of their last
visit. When estimating the cumulative incidences of molecular remissions,
Table 1. Patients’ characteristics
n Imatinib 400 Imatinib+IFN Imatinib+AraC Imatinib after IFN Imatinib 800 Total
Age (years), median (range) 1538 53 (16–88) 53 (16–83) 52 (18–79) 53 (18–87) 51 (18–85) 53 (16–88)
% Male 1538 61% 59% 63% 63% 59% 60%
% Smoker 1326 21% 16% 21% 20% 20% 19%
Karnofsky index (%), median (range) 1394 100 (70–100) 100 (50–100) 100 (70–100) 100 (70–100) 100 (50–100) 100 (50–100)
Hemoglobin (g/dl), median (range) 1524 12.4 (4.9–17.5) 12.2 (6.2–17.7) 12.5 (6.7–15.9) 12.9 (8.1–17.6) 12.2 (4.7–19.1) 12.3 (4.7–19.1)
WBC (× 109/l), median (range) 1531 77 (5.7–582) 89 (2.8–630) 58 (2.9–529) 56 (3.2–456) 79 (2.6–570) 76 (2.6–630)
Platelets ( × 109/l), median (range) 1533 382 (58–2419) 343 (49–3020) 403 (34–2799) 390 (44–2205) 386 (39–2716) 374 (34–3020)
Eosinophils (%), median (range) 1530 2 (0–20) 2 (0–12) 2 (0–14) 2 (0–14) 2 (0–16) 2 (0–20)
Basophils (%), median (range) 1526 3 (0–22)a 3 (0–20) 4 (0–21) 3 (0–17) 4 (0–26) 3 (0–26)
Blasts in blood (%), median (range) 1525 1 (0–17)b 1 (0–16) 1 (0–19) 0 (0–16) 1 (0–17) 1 (0–19)
Spleen size (cm below costal margin),
median (range)
1529 2 (0–28) 2 (0–38) 0 (0–20) 0 (0–19) 2 (0–30) 2 (0–38)
Euro score, n (%) 1527
Low — 142 (36) 150 (35) 55 (35) 48 (38) 159 (38) 554 (36)
Intermediate — 205 (51) 226 (53) 81 (51) 79 (62) 202(48) 793 (52)
High — 51 (13) 49 (12) 22 (14) 1 (1) 57 (14) 180 (12)
Sokal score, n (%) 1513
Low 140 (36) 164 (39) 62 (39) 51 (40) 153 (37) 570 (38)
Intermediate 155 (40) 164 (39) 53 (34) 58 (45) 152 (37) 582 (38)
High 97 (25) 92 (22) 42 (27) 19 (15) 111 (27) 361 (24)
EUTOS score, n (%) 1523
Low 348 (88) 384 (90) 139 (88) 118 (92) 352 (85) 1341 (88)
High 49 (12) 44 (10) 19 (12) 10 (8) 60 (15) 182 (12)
ELTS score, n (%) 1521
Low 212 (54) 236 (55) 106 (67) 80 (62) 235 (57) 869 (57)
Intermediate 123 (31) 136 (32) 35 (22) 40 (31) 116 (28) 450 (30)
High 60 (15) 55 (13) 17 (11) 9 (7) 61 (15) 202 (13)
BCR-ABL1 transcript type, n (%) 1506
b2a2 147 (38) 192 (46) 54 (35) 43 (34) 160 (39) 596 (40)
b3a2 178 (46) 167 (40) 69 (45) 57 (46) 187 (45) 658 (44)
b2a2 and b3a2 54 (14) 55 (13) 29 (19) 24 (19) 61 (15) 223 (15)
Atypical transcripts 10 (2) 8 (1) 3 (1) 1 (1) 7 (1) 29 (1)
Abbreviations: ELTS, European treatment and outcome study (EUTOS)-long-term-survival; IFN, interferon-α; WBC, white blood cells. There were no significant
differences between the treatment groups. aOne patient with 66% basophils (basophil leukemia). bOne patient with ambivalent findings: 30% blasts in blood,
7% blasts in the marrow.
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patients were censored when they received a 2G-TKI. No patient was removed
from the study except at patient’s request (n=14).
Cytogenetic and molecular analyses
Cytogenetic and molecular diagnostics were performed as described.6
Testing for residual BCR-ABL1 transcripts24,25 was done in two standardized
and accredited laboratories with defined conversion factors for equiva-
lence of tests (Mannheim and MLL Munich). Confirmed MR4, MR4.5 and MR5
were defined as a reduction of residual BCR-ABL1 transcripts of ⩾ 4, ⩾ 4.5
and ⩾ 5 logs compared with the standardized baseline in two consecutive
analyses.24,25 Testing was restricted to patients expressing b2a2 and/or
b3a2 transcripts. For a negative quantitative reverse-transcription
polymerase chain reaction, the number of ABL1 transcripts used for nested
PCR had to be ⩾ 10 000 for MR4, ⩾ 32 000 for MR4.5 and ⩾ 100 000 for MR5.
Mutation analysis was performed according to the ELN
recommendations.26
Sample size estimation
At first, differences in probability of MMR at 12 months were investigated.3 If
the null hypothesis of equal probabilities could be rejected, OS differences
between IM400 mg and IM800 mg were examined. Assuming an alpha=0.05,
a 5-year recruitment, and an additional 5-year follow-up, it would be possible
to identify a survival difference with a power of at least 80%, if patients in the
IM400 mg arm had a 5-year survival probability of 90% and in the IM800 mg
arm of at least 95% or not more than 84%, and if n=400 patients were
randomized to each arm. Exponential distribution was assumed and survival
probabilities were compared with the log-rank test.27,28
Statistical analyses
OS and PFS were analyzed using Kaplan–Meier curves and log-rank tests.
To estimate relative survival, OS probabilities were adjusted by survival
probabilities of matched German population data from the Human
Mortality Database for each year of diagnosis in CML-study IV29 with
regard to sex and individual age at diagnosis.30 Cumulative incidences
were calculated under consideration of competing risks31 of death defined
by accelerated phase, BC and death from any cause. Comparisons between
cumulative incidences were performed by the Gray test32 and prognostic
impact of remissions determined by landmark analyses.33 Besides the
cumulative incidences of molecular responses, all analyses were by
intention to treat. Level of significance was 0.05 two sided. For estimation
of relative survival probabilities software R (version 3.0.3.3, GNU General
Public License, R Foundation, Vienna, Austria) was applied.34 All other
calculations were performed with SAS software version 9.3 (SAS Institute,
Cary, NC, USA).
Ethics
The protocol followed the Declaration of Helsinki and was approved by the
ethics committees of the Medizinische Fakultät Mannheim and of
participating centers. Written informed consent was obtained from all
patients before randomization.
RESULTS
Patients
From July 2002 to March 2012, 1551 newly diagnosed CML
patients in CP were randomized, 1536 were evaluable, 400 for
IM400 mg, 430 for IM plus IFN, 158 for IM plus cytarabine, 128 for
Figure 1. Flow diagram of all 1551 randomized patients. Ara-C, cytarabine; CP, chronic phase; IC, informed consent; IFN, interferon-α;
IM, imatinib; OS, overall survival; SCT, stem cell transplantation; TKI, tyrosine kinase inhibitor.
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IM after IFN and 420 for IM800 mg. Patients were recruited by 210
centers in Germany, Switzerland and the Czech Republic. Patients’
characteristics are shown in Table 1. Median age was 53 years,
60% of patients were male. Euro score was low-risk in 36%,
intermediate in 52% and high-risk in 12% of patients. In the arm
IM plus IFN, IFN was added to IM400 mg for a median of 1.1 years.
After 10 years, six patients still received IFN. In the IM after IFN-
failure arm, the median time on IFN monotherapy was 0.5 years.
After 10 years, one patient still continued in remission on IFN
monotherapy. The median time on low-dose cytarabine was 1.3
years. The main reason for discontinuation of IFN and cytarabine
was intolerance. In the IM800 mg arm, the dose could be reduced
according to tolerability, the median IM-dose declined from
a maximum of 645 mg/day in the 2nd quarter of year 1 to 400
(200–800) mg/day in year 4. The median dose in the IM400 mg
arm was 400 (200–800) mg/day with a dose increase reported in
86 patients. Median observation time was 9.5 years (11.8 years for
IM plus cytarabine and IM after IFN and 8.3 years for IM800 mg).
The flow of patients in the five study arms is shown in Figure 1. At
the last evaluation, at least 728 of 1181 patients under observation
(62%) still received IM.
Survival
In all, 10-year OS of all patients was 82% (95% confidence interval
(CI): 80; 84) (Figure 2a), 10-year PFS (95% CI: 78; 82) 80%. 10-year
OS was 80% with IM400 mg, 84% with IM plus IFN, 84% with IM
plus cytarabine, 79% with IM after IFN-failure and 79% with
IM800 mg, (Figure 2b). In all, 10-year PFS was 80% with IM400 mg,
83% with IM plus IFN, 82% with IM plus cytarabine, 75% with IM
after IFN and 77% with IM800 mg (Supplementary Figure 1).
Adjusted for matched general population data, 10-year relative
survival probability was 92% (95% CI: 89; 95) (Figure 2a; 91% for
IM400 mg, 94% for IM plus IFN, 94% for IM plus cytarabine, 93%
for IM after IFN and 87% for IM800 mg) and 96% (95% CI: 88; 99)
for the 594 patients with BCR-ABL1 ⩽ 1% (Figure 2c). Two-hundred
seventy five patients died, 23 after stem cell transplantation in first
CP. Of patients not transplanted in first CP, more deaths were
unrelated to CML (n= 169, 67%) than due to CML (n= 83, 33%).
The 10-year probability of death due to CML was 6%, of death
unrelated to CML 12% (Figure 2d). In all, 10-year OS and PFS
according to Euro score and treatment are shown in
Supplementary Table 1. Whereas Euro low-risk patients had
significantly better survival than higher-risk patients, survival with
Figure 2. Long-term survival evaluation. (a) Overall survival and relative survival of all 1536 CML-patients. (b) Overall survival according to treatment
groups over time. (c) Survival by landmark analysis at 6 months according to achieving and not achieving the milestone ⩽1% BCR-ABL1IS at
6 months. The 594 responders have a significantly better survival and show a 10-year relative survival of 96%. The 385 non-responders include slow
responders with very good prognosis and high-risk patients requiring attention to patients’ and disease risk factors. (d) Survival according to causes
of death defined as related or unrelated to CML. AraC, cytarabine; IFN, interferon-α; OS, overall survival; RS, relative survival; IM, imatinib.
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Figure 3. Overall survival by disease risk (Euro-score). (a) Low, (b) intermediate, (c) high. AraC, cytarabine; IFN, interferon-α; OS, overall survival;
IM, imatinib.
Table 2. Causes of death
IM 400 mg IM+IFN IM+cytaribine IM after IFN-failure IM 800 mg Total
Total deaths (n) 75 69 39 30 62 275
Causes (n)
Progression to AP/BC 17 15 9 6 20 67
Transplantation related 6 9 7 4 5 31
Infection in CP 7 6 1 2 4 20
Secondary malignancy 16 12 3 6 7 44
Bleeding 1 2 0 0 1 4
Cardiopulmonary 10 10 5 6 9 40
Renal insufficiency 2 1 1 1 2 7
Thromboembolic/ischemic (not cardiac) 1 1 2 1 3 8
Suicide 1 1 0 0 0 2
Others 3 4 2 1 2 12
Unknown 11 8 9 3 9 40
Abbreviations: AP, accelerated phase; BC, blast crisis; CP, chronic phase; IFN, interferon-α; IM, imatinib. n indicates number of patients.
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any treatment was not significantly different from IM400 mg at
any risk level (Figure 3) nor was a significant difference detectable
by any other risk score.23,35,36 The non-CML causes of death
correspond to those observed in the general population (Table 2).
The cumulative incidences of death related and unrelated to
CML were not different between the five treatment arms
(Supplementary Figure 2), whether stratified for ELTS or not.23
Multivariate analysis for impact on survival of variables at
diagnosis: risk score, comorbidities, major-route additional chro-
mosomal aberrations, smoking and treatment center (academic vs
others) influenced survival significantly, but not gender, transcript-
type or initial treatment selection (Table 3).
Power
With n= 400 randomized to IM400 mg and n= 420 randomized to
IM800 mg, an accrual time of 6.75 years across treatment arms and
an additional follow-up of 4.25 years, the power would have been
above 80% to observe OS differences, if the assumptions for the
sample size estimation (see Methods) had been correct. In fact,
survival probabilities at 5 years were 89% (95% CI: 86%; 92%) and
92% (95% CI: 88%; 94%), respectively. At 10 years, the difference in
OS probability was only 1%. The hazard ratio of IM400 mg to
IM800 mg was 1.091 (95% CI: 0.767; 1.550) instead of 2 or 0.61.
Switching to 2G-TKI
Four-hundred seven patients (26.5%) were switched to another
TKI, mostly dasatinib or nilotinib, due to intolerance or resistance.
Seven patients were switched to bosutinib, 5 to ponatinib, and 57
to more than one TKI. The median time to switching was
34 months. Switching was evenly distributed between treatment
arms (Figure 1) arguing against an influence on comparative
survival analyses. Censoring at the time of switching raised 10-year
OS by 3% across treatment arms, indicating that predominantly
poorer risk patients were switched.
Mutations and progressions
One-hundred ten of 541 analyzed patients (20,3%) had mutations
of the BCR-ABL1-kinase domain, 70 (64%) had known resistance
mutations (T315I (n= 33), E255K (n= 11), Y253H (n= 11), F359C
(n= 8), G250E (n= 4) and F486S (n= 3)) and 73 (66%) were
switched to 2G-TKI. More high-risk patients (31.5%) than low
(16.9%) and intermediate risk patients (18.7%) had mutations.
One-hundred fifteen patients fulfilled the criteria of progression to
accelerated phase and BC, of which 89 had mutation analyses
which were positive in 35 (39%). Eighty-seven patients progressed
to BC. The 10-year cumulative incidence of BC was 5.8% (95% CI:
4.7%; 7.1%). Most BC occurred in the first two years, but some
continued to occur later during the entire observation time
(Figure 4). Median survival after BC was 7.9 months across all
treatment arms. Thirty-eight patients had myeloid, 28 lymphoid
BC, in 21 patients the type was mixed or unknown.
Transplantation
One-hundred thirty-eight patients were transplanted, 91 in first
CP. Median age at transplantation was 41 (16–65) years, 94 (68%)
were male. Eight-year survival after transplantation in first CP was
73%, of those transplanted not in first CP 38%.
Cytogenetic and molecular responses
By 10 years, the cumulative rates of complete cytogenetic
remission were 77% (95% CI: 75; 79), of molecular response
Table 3. Multivariate analysis for impact on survival (n= 1252)
Variable Regression
coefficient
Standard error P-value Hazard ratio Type-3-test
Therapy IM-after-IFN-failure vs IM 400 0.288 0.254 0.256 1.334 0.676
IM 800 vs IM 400 0.033 0.207 0.875 1.033
IM+cytarabine vs IM 400 0.157 0.244 0.519 1.170
IM+IFN vs IM 400 −0.069 0.199 0.727 0.933
ELTS-score Low vs high risk − 0.778 0.210 o0.001 0.459 o0.001
Intermediate vs high risk 0.061 0.208 0.770 1.062
Treatment center Academic center better than community
hospital
0.416 0.181 0.021 1.515 0.012
Academic center better than private
practice
0.570 0.199 0.004 1.768 0.004
Comorbidity (Charlson
index)
Per point (age not considered)a 0.417 0.050 o0.001 1.518 o0.001
Gender Male vs female 0.181 0.154 0.240 1.199 0.240
Transcript type b2a2 vs b3a2 0.088 0.157 0.574 1.092 0.713
b2a2+b3a2 vs b3a2 0.158 0.208 0.447 1.171
Smoking habit Smoker vs non-smoker 0.547 0.169 0.001 1.728 0.001
Major-route ACA Major-route ACA vs no major-route ACA at
diagnosis
1.814 0.392 o0.001 6.137 o0.001
Abbreviations: ACA, additional chromosomal aberration; ELTS, EUTOS-long-term survival; IM, imatinib, IFN, interferon-α. Also better education (bachelor vs no
bachelor) had an impact (Po0.001), but was not independent of smoking and selection of treatment center. aAge considered by ELTS-score.
Figure 4. Incidence of blast crisis over time.
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equivalent to complete cytogenetic remission37 (⩽1% BCR-ABL1IS)
91% (95% CI: 89; 94), of MMR 88% (95% CI: 86; 90), of MR4 83%
(95% CI: 80; 85), and of MR4.5 70% (95% CI: 67; 73). The molecular
responses according to treatment over time are shown in Table 4.
Compared with IM400 mg, significantly faster responses were
observed with IM800 mg for MR2-MR4, but not for MR5. A faster
response was observed with IM800 mg also for MR4.5, but this was
not significant (P= 0.053). No patient who stopped IM in deep
molecular remission or because of other reasons has died.
Survival by response milestones
One-thousand three-hundred and eleven patients had molecular
tests at response milestones. Patients who reached ≤ 10% BCR-
ABL1IS at 3 months (n=598 of 873 (68.5%)), ⩽1% BCR-ABL1IS
(equivalent to complete cytogenetic remission) at 6 months (n=594
of 979 (61%)), or ⩽ 0.1% BCR-ABL1IS (MMR) at 12 months (n=469 of
914 (54.7%)) had significantly better survival than those who did not
regardless of therapy. Supplementary Table 2 summarizes survival
and response according to milestones at 3, 6 and 12 months.
Figure 2c shows the landmark analysis at 6 months across
treatment groups with a survival difference of 6.4% after 10 years.
When patients reaching and not reaching milestones were analyzed
by therapy, the faster response with one therapy (IM800 mg) did
not translate into a detectable survival advantage.
Safety
A detailed safety analysis38 showed frequent, but mostly mild
adverse drug reactions. Over the last 3 years, no new safety
concerns have evolved. No serious late toxicity was observed.
Observation time is still short, late effects in cancer survivors may
well appear decades later. Continuous monitoring of patients
under TKI-treatment appears mandatory.
DISCUSSION
The data of this large randomized 5-arm treatment optimization
study with the long median observation time of 9.5 years showed
that high survival probabilities (82% at 10 years) can be achieved
with IM-based therapy. This corresponds well to the 83.3% survival
after 10 years in IRIS.2 The study further demonstrates that with
regard to survival none of the experimental treatments is superior
to IM400 mg. Interestingly, the faster and earlier cytogenetic and
molecular responses of the experimental arm IM800 mg3,8 did not
translate into longer survival. The lack of survival differences
between treatment arms may be explained by relatively few
events attributable to CML, considering an overall 10-year relative
survival of 92%, matching well with the 10-year CML mortality of
just 6% and pointing to the relevance of non-CML causes of
mortality. Similar observations have been reported with 2G-TKI
after median observation times of 5 years.17,18
CML-study IV was powered to detect an OS difference between
the IM400 mg and IM800 mg arms of at least 5% 5 years after
diagnosis, but due to survival probabilities of 89% and 92%,
respectively, at 5 years, the difference was only 3%, and only 1% at
10 years. Any therapy aiming at improving survival above what is
currently achieved with standard IM would have to further
decrease the incidence and/or mortality of BC. The benefit of
such therapy would have to be weighed against its toxicity.18,39
Patients that reached response milestones of ⩽ 10% BCR-ABL1IS
by 3 months, ⩽ 1% by 6 months or ⩽ 0.1% by 12 months had
higher survival probabilities than those who did not—regardless
of treatment. That this survival advantage was not detectable by
analysis according to treatment group is probably due to the small
survival difference (ca. 6% after 10 years) and the lower number of
patients reaching milestones. Also the composition of the group
not reaching the milestones has to be taken into account
consisting of slow responders with very good survival as well as
higher proportions of high-risk patients and progressions to BC.
Given the excellent overall prognosis of CML, considerably larger
patient numbers than in this already large study are required to
detect the expected small survival difference.
Survival as shown by multivariate analysis was influenced more
by disease biology, patients’ demographics and microeconomic
elements than by initial treatment selection indicating that more
attention has to be paid to non-CML factors in order to improve
outcome of CML-patients. It is remarkable that a single tablet
per day of a well tolerable drug reverses the course of a formerly
uniformly fatal malignant disease and moves CML close to a
potential cure. This is in line with reports of relapse-free survival
following discontinuation of IM after deep and durable
responses.40 The 10-year deep molecular remission rates of
70–80% in this study indicate that the majority of IM-treated
patients are candidates for treatment discontinuation.
Our experience with the two IFN-arms might provide useful
information. Neither IFN-arm achieved a survival advantage over
IM400mg, but OS in the IM-after-IFN-failure arm, which resembles
the IFN-arm of IRIS, was not inferior to that of the IM400mg arm
(with the limitation that no Euro-high-risk patients were randomized
to IM-after-IFN). It is also noteworthy that the simultaneous
application of IM and IFN may have an advantage, since, by intention
to treat analysis, it showed a significantly better PFS than the
consecutive application of IM after IFN-failure. As favorable response
results on IM in combination with IFN were reported by others,9,10 it
appears worthwhile to further follow this line of treatment.
Four-hundred seven patients (26.5%) were switched to one or
more other TKI. As switching was evenly distributed between
treatment arms an influence on survival comparisons is unlikely.
We cannot determine to what extent survival was improved by
switching to 2G-TKI in this study, as this was not planned
prospectively. Censoring at the time of switching, however,
improved survival by about 3% across treatment arms indicating
that predominantly poorer risk patients had been switched. Also
progression was distributed evenly. Eighty-seven patients (5.8%)
developed BC of whom 67 died in spite of multiple lines of
therapy including intensive chemotherapy and transplantation.
In conclusion, the results show that monotherapy with IM400 mg
achieved a survival not much different from that of the general
population, and that survival with CML is currently more
determined by patients’ and disease factors than by initial
treatment selection. More attention has to be paid to these factors
in a personalized approach. Comorbidities should be addressed and
smoking discouraged. Although improvements are also needed for
the subgroups of refractory disease, more life-time can currently be
gained by carefully addressing non-CML determinants of survival.
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